行情

JAGX

JAGX

Jaguar Health
NASDAQ

实时行情|Nasdaq Last Sale

0.4956
+0.0155
+3.23%
盘后: 0.5196 +0.024 +4.84% 17:04 04/01 EDT
开盘
0.5200
昨收
0.4801
最高
0.5473
最低
0.4811
成交量
36.33万
成交额
--
52周最高
24.50
52周最低
0.3507
市值
2,535.16万
市盈率(TTM)
-0.0055
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测JAGX价格均价为4.000,最高价位5.00,最低价为3.000。

EPS

JAGX 新闻

更多
  • 沪指走高翻红 疫情数据双重打击、隔夜美股重挫4.4%
  • 新浪财经 · 14分钟前
  • 海上石油库存逼近2009年的纪录高位 因库存过剩加剧
  • 新浪财经综合 · 1小时前
  • 国际大米价格创六年半新高
  • 新浪财经综合 · 1小时前
  • 英航或临时裁减3.6万员工
  • 新浪财经 · 1小时前

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

JAGX 简况

Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
展开

微牛提供Jaguar Health Inc(NASDAQ-JAGX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的JAGX股票新闻,以帮助您做出投资决策。